{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T07:32:31Z","timestamp":1773300751276,"version":"3.50.1"},"reference-count":38,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1666,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1111\/j.1600-0609.2010.01570.x","type":"journal-article","created":{"date-parts":[[2011,1,3]],"date-time":"2011-01-03T02:18:24Z","timestamp":1294021104000},"page":"216-225","source":"Crossref","is-referenced-by-count":6,"title":["Imatinib increases cytotoxicity of melphalan and their combination allows an efficient killing of chronic myeloid leukemia cells"],"prefix":"10.1111","volume":"86","author":[{"given":"Cesarina","family":"Giallongo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piera","family":"La Cava","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniele","family":"Tibullo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nunziatina","family":"Parrinello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignazio","family":"Barbagallo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vittorio","family":"Del Fabro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Stagno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Concetta","family":"Conticello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Romano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annalisa","family":"Chiarenza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe A.","family":"Palumbo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Di Raimondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,2,8]]},"reference":[{"key":"10.1111\/j.1600-0609.2010.01570.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1182\/blood.V91.5.1700","article-title":"Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3","volume":"91","author":"Amarante-Mendes","year":"1998","journal-title":"Blood"},{"key":"10.1111\/j.1600-0609.2010.01570.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S1470-2045(07)70342-X","article-title":"Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia","volume":"8","author":"Apperley","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1111\/j.1600-0609.2010.01570.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1182\/blood-2004-03-0826","article-title":"Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia","volume":"104","author":"Baccarani","year":"2004","journal-title":"Blood"},{"key":"10.1111\/j.1600-0609.2010.01570.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1182\/blood.V86.3.1148.1148","article-title":"BCR-ABL-mediated inhibition of apoptosis with delay of G2\/M transition after DNA damage: a mechanism of resistance to multiple anticancer agents","volume":"86","author":"Bedi","year":"1995","journal-title":"Blood"},{"key":"10.1111\/j.1600-0609.2010.01570.x-BIB5|cit5","first-page":"1942","article-title":"Multisystem stem cell failure after apparent recovery from alkylating agents","volume":"38","author":"Botnick","year":"1978","journal-title":"Cancer Res"},{"key":"10.1111\/j.1600-0609.2010.01570.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/0140-6736(90)91313-Y","article-title":"Autotransplants in chronic myelogenous leukaemia: strategies and results","volume":"335","author":"Butturini","year":"1990","journal-title":"Lancet"},{"key":"10.1111\/j.1600-0609.2010.01570.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1182\/blood-2002-10-3207","article-title":"p210 BCR\/ABL kinase regulates nucleotide excision repair (NER) and resistance to UV radiation","volume":"102","author":"Canitrot","year":"2003","journal-title":"Blood"},{"key":"10.1111\/j.1600-0609.2010.01570.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/300765a0","article-title":"A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia","volume":"300","author":"de Klein","year":"1982","journal-title":"Nature"},{"key":"10.1111\/j.1600-0609.2010.01570.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"914","DOI":"10.3324\/haematol.2009.016766","article-title":"Efficacy of escalated imatinib combined with cytarabine in newly diagnosed patients with chronic myeloid leukemia","volume":"95","author":"Deenik","year":"2009","journal-title":"Haematologica"},{"key":"10.1111\/j.1600-0609.2010.01570.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1182\/blood-2007-08-107482","article-title":"Dose-finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia","volume":"111","author":"Deenik","year":"2008","journal-title":"Blood"},{"key":"10.1111\/j.1600-0609.2010.01570.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"4808","DOI":"10.1182\/blood-2008-07-077958","article-title":"Translation of the Philadelphia chromosome into therapy for CML","volume":"112","author":"Druker","year":"2008","journal-title":"Blood"},{"key":"10.1111\/j.1600-0609.2010.01570.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells","volume":"2","author":"Druker","year":"1996","journal-title":"Nat Med"},{"key":"10.1111\/j.1600-0609.2010.01570.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1182\/blood-2004-08-3373","article-title":"Punish the parent not the progeny","volume":"105","author":"Elrick","year":"2005","journal-title":"Blood"},{"key":"10.1111\/j.1600-0609.2010.01570.x-BIB14|cit14","first-page":"3","article-title":"Stem cells, clonality and leukemia","volume":"39","author":"Gale","year":"1994","journal-title":"Gematol Transfuziol"},{"key":"10.1111\/j.1600-0609.2010.01570.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1200\/JCO.1998.16.7.2321","article-title":"Cellular pharmacodynamics and plasma pharmacokinetics of parenterally infused hydroxyurea during a phase I clinical trial in chronic myelogenous leukemia","volume":"16","author":"Gandhi","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1600-0609.2010.01570.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1046\/j.1365-2141.2002.03977.x","article-title":"Etoposide-mediated deregulation of the G2M checkpoint in myeloid leukaemic cell lines results in loss of cell survival","volume":"119","author":"Higginbottom","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1111\/j.1600-0609.2010.01570.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0145-2126(02)00163-7","article-title":"Fusion oncogenic tyrosine kinases alter DNA damage and repair after genotoxic treatment: role in drug resistance?","volume":"27","author":"Hoser","year":"2003","journal-title":"Leuk Res"},{"key":"10.1111\/j.1600-0609.2010.01570.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1200\/JCO.1985.3.2.192","article-title":"Intensive combination chemotherapy (ROAP 10) and splenectomy in the management of chronic myelogenous leukemia","volume":"3","author":"Kantarjian","year":"1985","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1600-0609.2010.01570.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1177\/1078155209340487","article-title":"Busulfan systemic exposure after oral administration of extemporaneously prepared high-dose busulfan capsules","volume":"16","author":"Kolbe","year":"2009","journal-title":"J Oncol Pharm Pract"},{"key":"10.1111\/j.1600-0609.2010.01570.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1515\/znc-2006-11-1219","article-title":"Imatinib (STI571) inhibits DNA repair in human leukemia oncogenic tyrosine kinase-expressing cells","volume":"61","author":"Majsterek","year":"2006a","journal-title":"Z Naturforsch [C]"},{"key":"10.1111\/j.1600-0609.2010.01570.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.mrgentox.2005.10.010","article-title":"Imatinib mesylate (STI571) abrogates the resistance to doxorubicin in human K562 chronic myeloid leukemia cells by inhibition of BCR\/ABL kinase-mediated DNA repair","volume":"603","author":"Majsterek","year":"2006b","journal-title":"Mutat Res"},{"key":"10.1111\/j.1600-0609.2010.01570.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.biochi.2003.10.008","article-title":"ABL-fusion oncoproteins activate multi-pathway of DNA repair: role in drug resistance?","volume":"86","author":"Majsterek","year":"2004","journal-title":"Biochimie"},{"key":"10.1111\/j.1600-0609.2010.01570.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S1470-2045(01)00454-5","article-title":"Repair of DNA interstrand crosslinks: molecular mechanisms and clinical relevance","volume":"2","author":"McHugh","year":"2001","journal-title":"Lancet Oncol"},{"key":"10.1111\/j.1600-0609.2010.01570.x-BIB24|cit24","first-page":"2225","article-title":"ts BCR-ABL kinase activation confers increased resistance to genotoxic damage via cell cycle block","volume":"13","author":"Nishii","year":"1996","journal-title":"Oncogene"},{"key":"10.1111\/j.1600-0609.2010.01570.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/nprot.2006.5","article-title":"The comet assay: a method to measure DNA damage in individual cells","volume":"1","author":"Olive","year":"2006","journal-title":"Nat Protoc"},{"key":"10.1111\/j.1600-0609.2010.01570.x-BIB26|cit26","first-page":"876","article-title":"Interferon enhanced minimal residual disease detection in acute promyelocytic leukaemia","volume":"96","author":"Palumbo","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1111\/j.1600-0609.2010.01570.x-BIB27|cit27","first-page":"454","article-title":"Chlorambucil drug resistance in chronic lymphocytic leukemia: the emerging role of DNA repair","volume":"7","author":"Panasci","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1111\/j.1600-0609.2010.01570.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1046\/j.0007-1048.2001.03331.x","article-title":"Melphalan treatment in patients with myelofibrosis with myeloid metaplasia","volume":"116","author":"Petti","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1111\/j.1600-0609.2010.01570.x-BIB29|cit29","first-page":"57","article-title":"A phase I and pharmacokinetic study of melphalan using a 24-hour continuous infusion in patients with advanced malignancies","volume":"6","author":"Pinguet","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1111\/j.1600-0609.2010.01570.x-BIB30|cit30","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.cbpc.2006.06.010","article-title":"Comparative study of DNA damage, cell cycle and apoptosis in human K562 and CCRF-CEM leukemia cells: role of BCR\/ABL in therapeutic resistance","volume":"144","author":"Pytel","year":"2006","journal-title":"Comp Biochem Physiol C Toxicol Pharmacol"},{"key":"10.1111\/j.1600-0609.2010.01570.x-BIB31|cit31","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nrc1567","article-title":"Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia","volume":"5","author":"Ren","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"10.1111\/j.1600-0609.2010.01570.x-BIB32|cit32","doi-asserted-by":"crossref","first-page":"8591","DOI":"10.1038\/sj.onc.1206087","article-title":"BCR\/ABL regulates response to DNA damage: the role in resistance to genotoxic treatment and in genomic instability","volume":"21","author":"Skorski","year":"2002","journal-title":"Oncogene"},{"key":"10.1111\/j.1600-0609.2010.01570.x-BIB33|cit33","doi-asserted-by":"crossref","first-page":"4189","DOI":"10.1128\/MCB.22.12.4189-4201.2002","article-title":"Fusion tyrosine kinases induce drug resistance by stimulation of homology-dependent recombination repair, prolongation of G(2)\/M phase, and protection from apoptosis","volume":"22","author":"Slupianek","year":"2002","journal-title":"Mol Cell Biol"},{"key":"10.1111\/j.1600-0609.2010.01570.x-BIB34|cit34","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1182\/blood.V100.1.224","article-title":"Repair of DNA interstrand crosslinks as a mechanism of clinical resistance to melphalan in multiple myeloma","volume":"100","author":"Spanswick","year":"2002","journal-title":"Blood"},{"key":"10.1111\/j.1600-0609.2010.01570.x-BIB35|cit35","first-page":"843","article-title":"A phase I study of intermittent continuous infusion high dose cytosine arabinoside for acute leukemia","volume":"4","author":"Stone","year":"1990","journal-title":"Leukemia"},{"key":"10.1111\/j.1600-0609.2010.01570.x-BIB36|cit36","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1038\/sj.leu.2402775","article-title":"Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugs","volume":"16","author":"Tipping","year":"2002","journal-title":"Leukemia"},{"key":"10.1111\/j.1600-0609.2010.01570.x-BIB37|cit37","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1053\/shem.2003.50047","article-title":"Imatinib mesylate in combination with other chemotherapeutic drugs: in vitro studies","volume":"40","author":"Tipping","year":"2003","journal-title":"Semin Hematol"},{"key":"10.1111\/j.1600-0609.2010.01570.x-BIB38|cit38","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1038\/sj.bjc.6600242","article-title":"Rationale for combination therapy of chronic myelogenous leukaemia with imatinib and irradiation or alkylating agents: implications for pretransplant conditioning","volume":"86","author":"Topaly","year":"2002","journal-title":"Br J Cancer"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0609.2010.01570.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1600-0609.2010.01570.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T05:26:45Z","timestamp":1625635605000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0609.2010.01570.x"}},"subtitle":["Cytotoxicity of melphalan and their combination"],"short-title":[],"issued":{"date-parts":[[2011,2,8]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,3]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1600-0609.2010.01570.x","relation":{},"ISSN":["0902-4441"],"issn-type":[{"value":"0902-4441","type":"print"}],"subject":[],"published":{"date-parts":[[2011,2,8]]}}}